Protocol Ledger

NCT05407246 · Phase II · COMPLETED

Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis

Interventional Phase II clinical trial protocol NCT05407246 sponsored by Tianjin Hemay Pharmaceutical Co in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-08-05 Enrollment: 90 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05407246
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)90 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05407246
Protocol FieldVerified Registry Value
NCT IdentifierNCT05407246
Consolidated Lead SponsorTianjin Hemay Pharmaceutical Co
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment90 participants (ACTUAL)
Registered Start Date2022-08-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05407246
Hospital Research SiteLocationSite Profile
Guangdong Provincial People's HospitalGuangzhou, ChinaOpen Hospital Dossier ->
Pingxiang People's HospitalPingxiang, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI